Abstract
Loss of muscle mass, also known as muscle atrophy, is prevalent in chronic diseases such as COPD. Due to its limiting effects on daily activities and quality of life, treatment regimens also focus on muscle mass recovery. Research into the GSK-3 protein, which is a negative regulator of muscle mass, shows that muscle mass recovery does not require inhibition of GSK-3 activity as observed during the recovery of atrophied muscle, although complete elimination of GSK-3 enhances the early phase of muscle mass recovery. These results offer insights into the mechanisms underlying muscle mass recovery which can be used to develop drugs specifically aimed at enhancing muscle mass maintenance and recovery in people suffering from chronic diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
